News

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 21, 2020.

Phenytoin is indicated for the treatment of tonic-clonic and psychomotor seizures in pediatric and adult patients.

The previously approved therapy is now indicated for treatment in pediatric patients age 2 to 10.

New data suggest a switch from natalizumab to a high efficacy disease-modifying therapy for patients with multiple sclerosis is more beneficial than switching to moderate efficacy therapy, including a lower risk of disease activity.

Despite the conventional need for patients to travel to MRI devices, the use of a point-of-care, portable scanner has proven to be a feasible method of acquiring clinically useful images.

Secondary endpoints and final results from the clinical study will be announced at the end of March 2020.

Patients 65 and under were more likely to develop seizures following a stroke than older patients.

The beneficial impact on stroke risk appeared to be greater in patients age 79 and younger than in the older patients examined.

Self-administration of the drug led to statistically significant motor status changes within 30 minutes of treatment.

In addition to significant improvements compared to placebo on Quantitative QMG scores, zilucoplan improved patients' activities of daily living and quality of life scores.

The model may help clinicians enact preventative measures for those with migraine with aura at an early stage.

These data confirm the need for consideration of these costs when prescribing treatments, and is of considerable importance as out of pocket costs continue to rise in the US.

The Prometra II offers a pressure-driven, valve-gated delivery mechanism that allows for novel programming modes of intermittent flow followed by periods of no flow—a feature unique to this device.